MetaCap

Compugen (CGEN) vs Sutro Biopharma (STRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Compugen (CGEN) has outperformed Sutro Biopharma (STRO) over the past year, gaining 20.3% versus a gain of 2.4%. Over five years, CGEN leads with a -59.5% price change compared with -94.7% for STRO. Compugen is the larger company by market cap ($174.3 million vs $142.8 million), about 1.2 times the size.

Compugen converts more of its revenue into profit, with a net margin of 48.6% versus -186.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGEN+20.26%STRO+2.38%
+407%+187%-33%
Nov 21, 20251 yearNov 20, 2026
CGEN-60.93%STRO-95.10%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGEN versus STRO key metrics
MetricCGENSTRO
Share price$1.84$8.60
Market cap$174.29M$142.77M
1-day change-2.13%-1.38%
YTD return+20.26%-25.67%
1-year return+20.26%+2.38%
5-year return-59.47%-94.68%
P/E ratio (TTM)4.72—
EPS (TTM)$0.39$-12.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.76M$102.48M
Revenue growth (YoY)+161.14%+65.18%
Net income (latest FY)$35.34M$-191.09M
Gross margin87.29%—
Operating margin43.05%-154.53%
Net margin48.57%-186.45%
52-week high$3.24$43.85
52-week low$1.43$7.15
Distance from 52-week high-43.21%-80.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+160.87%+419.65%
Average volume223.56K304.90K
Shares outstanding94.72M16.60M
Employees75129
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGEN has outperformed STRO by 17.9 percentage points over the past year.
  • Compugen is more profitable, keeping 48.6 cents of every revenue dollar as net income versus -186.5 cents for Sutro Biopharma.
  • Compugen grew revenue faster in its latest fiscal year (+161.14% vs +65.18%).

About Compugen

CGEN stock →

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees

About Sutro Biopharma

STRO stock →

Sutro Biopharma, Inc. operates as an oncology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees

CGEN vs STRO FAQ

Which is bigger, Compugen or Sutro Biopharma?

Compugen (CGEN) is larger, with a market capitalization of $174.29M compared with $142.77M for Sutro Biopharma (STRO).

Which stock has performed better over the past year, CGEN or STRO?

CGEN returned +20.26% over the past 12 months, compared with +2.38% for STRO (price return, excluding dividends). Past performance does not predict future results.

Are Compugen and Sutro Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons